Jean-Christophe IANOTTO
Hématologie Clinique-Institut de Cancéro-Hématologie · CHRU de Brest
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jean-Christophe IANOTTO as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:34 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03808805 · Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative NeoplasmsUniversity Hospital, Brest · completed · Myeloproliferative Disorder, Aquagenic Pruritus · principal investigator
- N/ANCT02910258 · Interferon-pegyle α2a Efficiency and Tolerance in MyelofibrosisUniversity Hospital, Brest · completed · Myelofibrosis · study director
- N/ANCT02897297 · Myeloproliferative Neoplastic Diseases Observatory From BrestUniversity Hospital, Brest · unknown · Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis · study director
- N/ANCT02893410 · Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET PatientsUniversity Hospital, Brest · completed · Polycythemia Vera, Essential Thrombocythemia · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:34 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.Haematologica · 2017140 citationsRCR 4.4
- Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.Clin Cancer Res · 201995 citationsRCR 4.5
- 59 citationsRCR 2.1
- Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.Int J Hematol · 201745 citationsRCR 1.8
- Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.Haematologica · 202219 citationsRCR 1.5
- Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).Br J Haematol · 202311 citationsRCR 1.1
- Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.Leukemia · 20217 citationsRCR 0.3
- Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status.Eur J Haematol · 20215 citationsRCR 0.2
- 3 citationsRCR 0.1
- 'MPN Genomic Calculator': real-life use in a young population with essential thrombocythaemia.Br J Haematol · 20201 citationsRCR 0.0